Shinichiro Fuse

Dr. Shinichiro (Shin) Fuse is a Partner at MPM Capital and focuses on investing in and building companies that develop innovative therapeutics. Shin is also an investment committee member of MPM’s impact collaboration with UBS that is a public/private crossover vehicle managed by MPM, and serves as interim Senior Vice President of ElevateBio, an MPM portfolio company focused on next-generation cell and gene therapies. Additionally, Shin supports MPM’s relationship with Astellas and is a board observer for CODA Biotherapeutics and Repare Therapeutics.

Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing. Previously, he was an Engagement Manager at Campbell Alliance (Syneos Health), where he worked with clients in the life science industry to support business development strategies and new product launches. Prior to joining Campbell Alliance, he was an Associate at PureTech Ventures, where he was a founding member of Vedanta Biosciences. He also serves as a columnist and contributing writer for Nikkei Biotech, the leading journal covering the biotech industry in Japan.

Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.